AMPLY Discovery

AMPLY Discovery is a biotechnology company developing an AI-driven drug discovery platform that combines machine learning, next-generation sequencing, and synthetic biology to identify novel biologic drug candidates from natural biological diversity.

The platform digitises biological molecules, identifies treatment targets, and produces candidates for laboratory validation.

Current programmes focus on an RNA interference therapy for acute myeloid leukaemia and an inhaled antimicrobial for drug-resistant tuberculosis, with assets developed for downstream out-licensing.